SGLT2 inhibitors (SGLT2i) are glucose-lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA) during therapy have been reported. The duration of glucosuria and inpatient course of SGLT2i-related DKA, however, is not well-characterized. We report 11 inpatient cases of SGLT2i-related DKA, including a subset of patients who experienced prolonged glucosuria and relapse of DKA during their hospitalization.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170458 | PMC |
| http://dx.doi.org/10.1002/edm2.117 | DOI Listing |
Publication Analysis
Top Keywords
prolonged glucosuria
8
glucosuria relapse
8
diabetic ketoacidosis
8
sglt2i-related dka
8
relapse diabetic
4
ketoacidosis sglt2-inhibitor
4
sglt2-inhibitor therapy
4
therapy sglt2
4
sglt2 inhibitors
4
inhibitors sglt2i
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!